New technologies in therapeutic antibody development

被引：53

作者：

Brekke, OH

Loset, GÅ

机构：

[1] Affitech New Technol, N-0349 Oslo, Norway

[2] Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway

来源：

CURRENT OPINION IN PHARMACOLOGY | 2003年 / 3卷 / 05期

关键词：

D O I：

10.1016/j.coph.2003.05.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The development of therapeutic antibodies took a sharp turn with the introduction of phage display technology over a decade ago. Antibodies are used in a whole range of disease fields, such as autoimmunity, cancer, inflammation and infectious diseases. Now, the first antibody derived from phage display technology has been approved in the US by the Food and Drug Administration. The antibody industry is continuously developing new and robust discovery platforms and novel antibody formats, which points to the versatility of antibodies as therapeutic and diagnostic agents.

引用

页码：544 / 550

页数：7

共 60 条

[21] In vitro selection and evolution of functional proteins by using ribosome display
Hanes, J
Pluckthun, A
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (10) : 4937 - 4942
[22] Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display
Hanes, J
Schaffitzel, C
Knappik, A
Plückthun, A
[J]. NATURE BIOTECHNOLOGY, 2000, 18 (12) : 1287 - 1292
[23] The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells
Hansen, MH
Nielsen, H
Ditzel, HJ
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (22) : 12659 - 12664
[24] Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites
He, MY
Taussig, MJ
[J]. NUCLEIC ACIDS RESEARCH, 1997, 25 (24) : 5132 - 5134
[25] Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci
He, YX
Honnen, WJ
Krachmarov, CP
Burkhart, M
Kayman, SC
Corvalan, J
Pinter, A
[J]. JOURNAL OF IMMUNOLOGY, 2002, 169 (01) : 595 - 605
[26] Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
Holliger, P
Brissinck, J
Williams, RL
Thielemans, K
Winter, G
[J]. PROTEIN ENGINEERING, 1996, 9 (03): : 299 - 305
[27] DIABODIES - SMALL BIVALENT AND BISPECIFIC ANTIBODY FRAGMENTS
HOLLIGER, P
PROSPERO, T
WINTER, G
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (14) : 6444 - 6448
[28] Engineered antibodies with increased activity to recruit complement
Idusogie, EE
Wong, PY
Presta, LG
Gazzano-Santoro, H
Totpal, K
Ultsch, M
Mulkerrin, MG
[J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (04) : 2571 - 2575
[29] Triabodies: Single chain Fv fragments without a linker form trivalent trimers
Iliades, P
Kortt, AA
Hudson, PJ
[J]. FEBS LETTERS, 1997, 409 (03) : 437 - 441
[30] Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics
Irving, RA
Coia, G
Roberts, A
Nuttall, SD
Hudson, PJ
[J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 248 (1-2) : 31 - 45

← 1 2 3 4 5 6 →